Noveris Health Sciences is trading at CA$0.07, down 7.14%, with no clear catalyst identified for the decline.
- No October 14 company announcement explaining the decline was found; the latest identified release was the September 9 annual-meeting update.
- A previously disclosed CA$7,878,792 convertible debenture was due to mature October 14, but no report links that date to the share-price move.
- The reported biotech-sector decline was for the prior session and does not establish a cause for this move.